The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus

Abstract

Objective. Despite wide use of the anti-CD20 monoclonal antibody rituximab in the treatment of B cell lymphomas, the mechanism by which it causes B cell depletion remains a subject of controversy. As part of an ongoing phase I/II trial of rituximab in the treatment of systemic lupus erythematosus (SLE), we sought to determine whether the effectiveness of B cell depletion was influenced by polymorphisms of Fc receptors (FcR) on effector cells.Methods. During rituximab treatment of 12 SLE patients, B cell depletion was monitored as a function of the serum rituximab level and Fc␥RIIa and Fc␥RIIIa genotypes at baseline and at 1 month and 2 months after treatment. FcR genotypes were determined by polymerase chain reaction. Serum levels of rituximab were measured by enzyme-linked immunosorbent assay (ELISA). B lymphocyte percentages were assessed by flow cytometry.Results. B cell depletion was highly variable in this patient cohort, with B cell percentages at the 1-2-month posttreatment nadir ranging from undetectable (<0.1 cell/ l) to 16% (ϳ30 cells/ l) of the total peripheral blood lymphocytes. At 2 months posttreatment, B cell percentages were highly correlated with both the serum rituximab level and the Fc␥RIIIa genotype (R 2 ‫؍‬ 0.75, P ‫؍‬ 0.002). The Fc␥RIIIa genotype was a significant independent predictor of the efficacy of B cell depletion (P ‫؍‬ 0.019). Conclusion. These results highlight the potential variability of B cell depletion by rituximab in the treatment of autoimmune disease and indicate that Fc receptors are an important determinant of that variability. The findings further suggest the importance of antibody-dependent cell-mediated cytotoxicity and/or apoptosis induction via Fc␥RIIIa-expressing effector cells in the mechanism of B cell depletion by this widely used monoclonal antibody.Rituximab is a chimeric mouse-human monoclonal antibody against the B cell-specific antigen CD20, a cell surface protein believed to function in B cell cycle initiation and differentiation (1-3). CD20 is first expressed in the early pre-B cell stage, and it remains present until terminal differentiation into plasma cells. The CD20 antigen represents an ideal target for immunotherapy of B cell lymphomas and, more recently, B cell-mediated autoimmune diseases due to its high and relatively sustained expression on malignant and normal B cells (4). Rituximab can effectively deplete B cells for several months and, as such, represents an effective treatment of B cell lymphoma (5).Several potential mechanisms have been proposed as mediators of the effects of rituximab (6). Thus, in vitro studies have demonstrated that rituximab bound to CD20ϩ cells induces complement-dependent cytotoxicity (CDC) and, in the presence of effector cells, antibody-dependent cell-mediated cytotoxicity (ADCC) (5). Additionally, rituximab can induce B cell apoptosis when crosslinked by Fc␥ receptor (Fc␥R)-bearing cells (7). The relative importance of antibody-mediated apoptosis, CDC, and ADCC in the depletion of B cells by rituximab remains to be...

Late‐onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections

“…However, the relationship of late-onset neutropenia to B lymphocyte depletion is intriguing, as patients with late-onset neutropenia had a longer and deeper B lymphocyte depletion and lower serum IgM levels than controls. This phenomenon may be related to a more pronounced B lymphocyte depletion reported in SLE patients with the Fc␥ receptor IIIa 158 V allele after rituximab treatment (10) and to lack of granulopoiesis coinciding with high levels of B lymphocyte-activating factor (11).…”

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitis

“…The pharmacokinetics and pharmacodynamics of rituximab are variable and are influenced by factors such as polymorphisms in Fc␥ receptor IIIa (29), proteinuria, and human antichimeric antibodies (30). The rituximab dosing regimen used to treat lymphoma (4 infusions of 375 mg/m 2 each given 1 week apart) results in an average total dose of 2.6 gm in a person weighing 70 kg.…”

The value of rituximab treatment in primary Sjögren's syndrome

“…Furthermore, the degree of B cell depletion was positively associated with clinical response in both RA and SLE [55,56]. SLE patients with a low-affinity FcγRIIIa genotype have less effective B cell depletion, as antibody-dependent cellular cytotoxicity, mediated by FcγRIIIa-positive effector cells (mostly NK cells), is impaired [57]. This genotype results in lower binding affinity of FcγRIIIa to anti-CD20 antibodies that are bound to the target B cells.…”